94-31394. Prospective Grant of Exclusive License: Neutralizing Monoclonal Antibodies for Respiratory Syncytial Virus

[Federal Register Volume 59, Number 245 (Thursday, December 22, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-31394]


[[Page Unknown]]

[Federal Register: December 22, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Prospective Grant of Exclusive License: Neutralizing Monoclonal 
Antibodies for Respiratory Syncytial Virus

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive world-wide license to practice the invention embodied in 
U.S. Patent Application SN 07/945,515 entitled ``Neutralizing 
Monoclonal Antibodies for Respiratory Syncytial Virus'' and related 
foreign patent applications to SmithKline Beecham Corporation, of 
Philadelphia, Pennsylvania. The patent rights in this invention have 
been assigned to the United States of America.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
It is anticipated that this license may be limited to the fields of 
treatment and prevention of RSV infection in humans. This prospective 
exclusive license may be granted unless within 60 days from the date of 
this published notice, NIH receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The patent application describes human monoclonal antibodies which 
bind and neutralize respiratory syncytial virus (RSV) antigenic 
subgroups A and B. These monoclonal antibodies may be used alone or in 
mixtures to treat or prevent RSV infection. Cell lines secreting the 
monoclonals are also described.

ADDRESSES: Requests for a copy of this patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Robert Benson, Patent Advisor, Office of 
Technology Transfer, National Institutes of Health, 6011 Executive 
Blvd., Box 13, Rockville, MD 20852. Telephone: [phone], X267; 
Facsimile: [phone]. Applications for a license filed in response 
to this notice will be treated as objections to the grant of the 
contemplated license. Only written comments and/or applications for a 
license which are received by NIH within sixty (60) days of this notice 
will be considered. A signed Confidential Disclosure Agreement will be 
required to receive a copy of the patent application.

    Dated: December 12, 1994.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-31394 Filed 12-21-94; 8:45 am]
BILLING CODE 4140-01-P